Company intelligence / Profile preview

ACCBT

Gurnee, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Lead program (CBT300) demonstrated strong preclinical efficacy as monotherapy or in combination for reversing drug/immune resistance in refractory cancers. Tumor regression rates up to 65%, 88% survival in resistant models, no toxicity observed. Not yet in human clinical trials—IND pending for Phase I in metastatic breast cancer with brain metastases.

Therapeutic areas: OncologyInfectious DiseasesNeurology
Modalities: BiologicPlatform therapySmall moleculeAntibody
Industry: Biotech

Partnerships

Cleveland Clinic (glioblastoma studies)Colorado State University (veterinary studies)US Army research division (viral therapy testing)

Beyond the preview

Go deeper on ACCBT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACCBT.

Explore the full profile